Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo
Daxor (DXR) showcased significant presence at the American College of Cardiology's 74th Annual Scientific Session and Expo in Chicago. A key session on Blood Volume Analysis (BVA) versus pressure measurement attracted over 400 clinicians. Duke University Medical Center presented new research confirming BVA as a more precise measure of congestion in heart failure patients.
Dr. Marat Fudim of Duke University Health emphasized that pressure-based assessments often misrepresent true volume status. The Duke study revealed that common proxy markers including urine output, weight change, and biomarkers CA-125 and NT-proBNP did not correlate with intravascular volume. The findings reinforce that volume management, rather than pressure management, should be the primary focus in heart failure treatment.
Daxor (DXR) ha mostrato una presenza significativa alla 74ª Sessione Scientifica Annuale e Expo del Collegio Americano di Cardiologia a Chicago. Una sessione chiave sull'Analisi del Volume Sanguigno (BVA) rispetto alla misurazione della pressione ha attratto oltre 400 clinici. Il Centro Medico della Duke University ha presentato nuove ricerche che confermano il BVA come una misura più precisa della congestione nei pazienti con insufficienza cardiaca.
Il Dr. Marat Fudim della Duke University Health ha sottolineato che le valutazioni basate sulla pressione spesso non rappresentano correttamente lo stato reale del volume. Lo studio di Duke ha rivelato che i comuni indicatori proxy, inclusi il volume di urina, il cambiamento di peso e i biomarcatori CA-125 e NT-proBNP, non correlavano con il volume intravascolare. I risultati rafforzano l'idea che la gestione del volume, piuttosto che quella della pressione, dovrebbe essere il focus principale nel trattamento dell'insufficienza cardiaca.
Daxor (DXR) mostró una presencia significativa en la 74ª Sesión Científica Anual y Expo del Colegio Americano de Cardiología en Chicago. Una sesión clave sobre el Análisis del Volumen Sanguíneo (BVA) frente a la medición de la presión atrajo a más de 400 clínicos. El Centro Médico de la Universidad de Duke presentó nueva investigación que confirma el BVA como una medida más precisa de la congestión en pacientes con insuficiencia cardíaca.
El Dr. Marat Fudim de Duke University Health enfatizó que las evaluaciones basadas en la presión a menudo no representan el verdadero estado del volumen. El estudio de Duke reveló que los marcadores proxy comunes, incluidos el volumen de orina, el cambio de peso y los biomarcadores CA-125 y NT-proBNP, no correlacionaban con el volumen intravascular. Los hallazgos refuerzan que la gestión del volumen, en lugar de la gestión de la presión, debería ser el enfoque principal en el tratamiento de la insuficiencia cardíaca.
Daxor (DXR)는 시카고에서 열린 미국 심장학회 제74회 연례 과학 세션 및 엑스포에서 중요한 존재감을 나타냈습니다. 혈액량 분석(BVA)과 압력 측정에 대한 주요 세션은 400명 이상의 임상의들을 끌어모았습니다. 듀크 대학교 의료 센터는 심부전 환자의 혼잡도를 보다 정확하게 측정하는 BVA에 대한 새로운 연구 결과를 발표했습니다.
듀크 대학교 헬스의 마라트 후딤 박사는 압력 기반 평가가 종종 실제 볼륨 상태를 잘못 나타낸다고 강조했습니다. 듀크 연구에서는 소변량, 체중 변화, 바이오마커 CA-125 및 NT-proBNP와 같은 일반적인 대리 지표가 혈관 내 볼륨과 상관관계가 없음을 밝혀냈습니다. 이 결과는 심부전 치료에서 압력 관리보다 볼륨 관리가 주요 초점이 되어야 함을 강화합니다.
Daxor (DXR) a montré une présence significative lors de la 74e Session Scientifique Annuelle et Expo du Collège Américain de Cardiologie à Chicago. Une session clé sur l'Analyse du Volume Sanguin (BVA) par rapport à la mesure de la pression a attiré plus de 400 cliniciens. Le Centre Médical de l'Université Duke a présenté de nouvelles recherches confirmant que le BVA est une mesure plus précise de la congestion chez les patients souffrant d'insuffisance cardiaque.
Le Dr Marat Fudim de Duke University Health a souligné que les évaluations basées sur la pression représentent souvent mal l'état réel du volume. L'étude de Duke a révélé que les marqueurs proxy courants, y compris le débit urinaire, le changement de poids et les biomarqueurs CA-125 et NT-proBNP, ne corrélaient pas avec le volume intravasculaire. Les résultats renforcent l'idée que la gestion du volume, plutôt que la gestion de la pression, devrait être l'objectif principal du traitement de l'insuffisance cardiaque.
Daxor (DXR) zeigte eine bedeutende Präsenz auf der 74. jährlichen wissenschaftlichen Sitzung und Expo des American College of Cardiology in Chicago. Eine wichtige Sitzung zur Blutvolumenanalyse (BVA) im Vergleich zur Druckmessung zog über 400 Kliniker an. Das Duke University Medical Center präsentierte neue Forschungsergebnisse, die BVA als präziseres Maß für Stauung bei Herzinsuffizienzpatienten bestätigen.
Dr. Marat Fudim von der Duke University Health betonte, dass druckbasierte Bewertungen oft den tatsächlichen Volumenstatus falsch darstellen. Die Duke-Studie zeigte, dass gängige Proxy-Marker wie Urinausstoß, Gewichtveränderung und die Biomarker CA-125 und NT-proBNP nicht mit dem intravasalen Volumen korrelierten. Die Ergebnisse bestätigen, dass das Volumenmanagement und nicht das Druckmanagement im Mittelpunkt der Behandlung von Herzinsuffizienz stehen sollte.
- Growing clinical recognition with 400+ attendees at ACC conference session
- New Duke University research validates BVA technology's superiority over traditional methods
- Scientific evidence shows unique value proposition in heart failure treatment
- None.
BVA and Pressure Session Attracted 400+ Clinicians; Duke University Showcased Valuable New BVA Findings in Dedicated Poster Presentation
Oak Ridge, TN, April 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces excellent visibility of Daxor’s technology at the premier global cardiology conference, the American College of Cardiology (ACC) 74th Annual Scientific Session and Expo held in Chicago from March 29-31st. New data presented from Duke University Medical Center confirmed blood volume analysis (BVA) as a more precise measure of congestion in heart failure patients along with a focus session on the value of BVA compared to less reliable pressure measurement in heart failure care.
At a standing-room-only session attended by over 400 participants, titled, “When Pressure ≠ Volume: Understanding Complex Hemodynamic Situations and Pitfalls,” Dr. Marat Fudim of Duke University Health emphasized that pressure-based assessments frequently misrepresent true volume status. The research reinforces that volume management, rather than pressure management, should be the cornerstone of heart failure treatment. “The intense interest in the session highlights how much the awareness of BVA is growing and the need for direct volume measurement is being increasingly recognized in the cardiology community,” said Michael Feldschuh, Daxor’s President and CEO.
New research findings were also showcased from the Duke study, “Correlation Between Changes in Total Blood Volume and Measures of Congestion During Heart Failure Hospitalization,” which revealed that the following commonly used proxy markers believed to be useful for volume care did not, in fact, correlate with intravascular volume:
- Urine output
- Weight change
- Biomarkers CA-125, NT–proBNP
“This research from Duke adds to the substantial body of evidence of the unique value of BVA and reinforces the urgent need for precision in managing congestion in heart failure,” said John L. Jefferies, MD, MBA, MPH, Chief Medical Officer, Daxor Corporation. “Traditional methods often mislead, relying on indirect markers that do not accurately reflect true blood volume status. BVA provides the clarity clinicians need to make informed decisions, optimize treatment, and ultimately improve patient outcomes.”
About ACC
The American College of Cardiology (ACC) envisions a world where science, knowledge and innovation optimize cardiovascular care and outcomes. We believe in the power of community. With more than 56,000 members worldwide spanning the entire cardiovascular team, we serve as the professional home for clinicians and researchers seeking the latest science, research, and education. United with our members, chapters, and global cardiovascular partners, we are focused on transforming cardiovascular care and improving heart health for all. For more information visit https://www.acc.org/.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What were the key findings of Duke University's research on DXR's Blood Volume Analysis?
How many clinicians attended DXR's BVA session at ACC 2025?
What advantages does DXR's Blood Volume Analysis offer over traditional pressure measurements?
When and where was DXR's Blood Volume Analysis technology presented at ACC?
